Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chronic myeloid leukemia stem cells: targeting therapeutic implications
Hanieh Mojtahedi, Niloufar Yazdanpanah, Nima Rezaei
Stem Cell Research & Therapy (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia
Govinda Poudel, Molly G. Tolland, Timothy P. Hughes, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3300-3300
Open Access | Times Cited: 39
The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia
Mohamed El‐Tanani, Hamdi Nsairat, Ismail Matalka, et al.
Pathology - Research and Practice (2024) Vol. 254, pp. 155161-155161
Open Access | Times Cited: 15
Unmasking the Deceptive Nature of Cancer Stem Cells: The Role of CD133 in Revealing Their Secrets
Julia Pospieszna, Hanna Dams-Kozłowska, Wachirawit Udomsak, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10910-10910
Open Access | Times Cited: 14
Acquired miR-142 deficit in leukemic stem cells suffices to drive chronic myeloid leukemia into blast crisis
Bin Zhang, Dandan Zhao, Fang Chen, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 14
Drug resistance in human cancers — Mechanisms and implications
Sudikshaa Vijayakumar, Raveena Dhakshanamoorthy, Akshaya Baskaran, et al.
Life Sciences (2024) Vol. 352, pp. 122907-122907
Closed Access | Times Cited: 6
Biology and Therapeutic Properties of Mesenchymal Stem Cells in Leukemia
Cheng-Hsien Wu, Te‐Fu Weng, Ju‐Pi Li, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2527-2527
Open Access | Times Cited: 4
Therapeutic Vaccines for Hematological Cancers: A Scoping Review of This Immunotherapeutic Approach as Alternative to the Treatment of These Malignancies
Fernando Augusto Siqueira Mathias, Maria Gabriela Reis Carvalho, Jerônimo Conceição Ruiz
Vaccines (2025) Vol. 13, Iss. 2, pp. 114-114
Open Access
Beyond TKIs: Advancing Therapeutic Frontiers with Immunotherapy, Targeted Agents, and Combination Strategies in Resistant Chronic Myeloid Leukemia
Imran Rashid Rangraze, Mohamed El‐Tanani, Adil Farooq Wali, et al.
Hemato (2025) Vol. 6, Iss. 1, pp. 6-6
Open Access
Unraveling the kinase code: Role of protein kinase in lung cancer pathogenesis and therapeutic strategies
Mena Fatma, Sana Parveen, Snober S. Mir
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189309-189309
Closed Access
Clinical applicability of the ELN2020 criteria for tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: insights from a multicenter retrospective study in real-world practice
Yuto Hibino, Shin Fujisawa, Katsumichi Fujimaki, et al.
Leukemia Research (2025), pp. 107689-107689
Closed Access
BCR-ABL: The Molecular Mastermind behind Chronic Myeloid Leukemia
Tara Shammas, Malalage N. Peiris, April N. Meyer, et al.
Cytokine & Growth Factor Reviews (2025)
Closed Access
Signaling pathways governing the behaviors of leukemia stem cells
Shirin Azizidoost, Ava Nasrolahi, Mohadeseh Sheykhi-Sabzehpoush, et al.
Genes & Diseases (2023) Vol. 11, Iss. 2, pp. 830-846
Open Access | Times Cited: 9
Zinc as a potential regulator of the BCR-ABL oncogene in chronic myelocytic leukemia cells
Bo Zhu, Longshuo Sun, Zhonghua Li, et al.
Journal of Trace Elements in Medicine and Biology (2024) Vol. 83, pp. 127407-127407
Closed Access | Times Cited: 2
State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia
David Frankhouser, Russell C. Rockne, Lisa Uechi, et al.
Leukemia (2024) Vol. 38, Iss. 4, pp. 769-780
Open Access | Times Cited: 2
Dynamic Single-Cell RNA-Seq reveals mechanism of Selinexor-Resistance in Chronic myeloid leukemia
Yunqi Cui, Yating Li, Jiamei Ji, et al.
International Immunopharmacology (2024) Vol. 134, pp. 112212-112212
Open Access | Times Cited: 2
PRMT1 Promotes the Self‐renewal of Leukemia Stem Cells by Regulating Protein Synthesis
Min Zhou, Yi Huang, Ping Xu, et al.
Advanced Science (2024)
Open Access | Times Cited: 2
CDS-DB, an omnibus for patient-derived gene expression signatures induced by cancer treatment
Zhongyang Liu, Ruzhen Chen, Lele Yang, et al.
Nucleic Acids Research (2023) Vol. 52, Iss. D1, pp. D1163-D1179
Open Access | Times Cited: 5
Growth Inhibitory and Pro-Apoptotic Effects of Hirsuteine in Chronic Myeloid Leukemia Cells through Targeting Sphingosine Kinase 1
Shan Gao, Tingting Guo, Shuyu Luo, et al.
Biomolecules & Therapeutics (2022) Vol. 30, Iss. 6, pp. 553-561
Open Access | Times Cited: 8
Critical Requirement of SOS1 for Development of BCR/ABL-Driven Chronic Myelogenous Leukemia
Carmela Gómez, Rósula García‐Navas, Fernando C. Baltanás, et al.
Cancers (2022) Vol. 14, Iss. 16, pp. 3893-3893
Open Access | Times Cited: 8
Co-treatment of Naringenin and Ketoprofen-RGD Suppresses Cell Proliferation via Calmodulin/PDE/cAMP/PKA Axis Pathway in Leukemia and Ovarian Cancer Cells
Havva Afshari, Shokoofe Noori, Bahareh Shokri, et al.
Deleted Journal (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 4
The stem cell-specific long non-coding RNAs in leukemia
Maryam Farzaneh, Sajad Najafi, Mohadeseh Sheykhi-Sabzehpoush, et al.
Clinical & Translational Oncology (2022) Vol. 25, Iss. 2, pp. 345-351
Closed Access | Times Cited: 7
siRNA-mediated downregulation of BATF3 diminished proliferation and induced apoptosis through downregulating c-Myc expression in chronic myelogenous leukemia cells
Reza Dabbaghipour, Vahid Khaze, Sahar Safaei, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 1
Antileukemic potential of methylated indolequinone MAC681 through immunogenic necroptosis and PARP1 degradation
Barbora Orlikova-Boyer, Anne Lorant, Sruthi Reddy Gajulapalli, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 1
Peripheral blood quantitation of CD26 positive leukemic stem cells as a predictor of tyrosine kinase inhibitor response in chronic myeloid leukemia
Nitin Chaudhary, Khaliqur Rahman, P. Gupta, et al.
International Journal of Laboratory Hematology (2024) Vol. 46, Iss. 5, pp. 862-868
Closed Access | Times Cited: 1
Anti-Leukemic Effects of Small Molecule Inhibitor of c-Myc (10058-F4) on Chronic Myeloid Leukemia Cells
Sara Zehtabcheh, Negar Sheikh‐Zeineddini, Amir-Mohammad Yousefi, et al.
Asian Pacific Journal of Cancer Prevention (2024) Vol. 25, Iss. 6, pp. 1959-1967
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top